Francisco Esteva: De-escalating neoadjuvant chemotherapy in HER2+ breast cancer
Francisco Esteva, Chief of the Division of Hematology and Medical Oncology at Lenox Hill Hospital, shared a post on LinkedIn:
“De-escalating neoadjuvant chemotherapy in HER2+ breast cancer: Can we achieve the same outcomes with less toxicity?
A new retrospective study from Lenox Hill Hospital and Northwell Cancer Institute highlights the potential of a de-escalated regimen—weekly paclitaxel and carboplatin (wPCP) combined with HER2-targeted therapy – for patients with early HER2-positive breast cancer.
The results are promising: this approach achieved comparable pathologic complete response (pCR) rates to the standard TCHP regimen while significantly reducing grade ≥3 toxicities, such as neutropenia and peripheral neuropathy.
This study, presented by Patricia Avancena at the 2024 San Antonio Breast Cancer Symposium suggests that patients with small, node-negative, or hormone receptor-positive HER2+ breast cancer may not require intensive chemotherapy, paving the way for more personalized, tolerable treatment options.
By reducing toxicity without compromising efficacy, wPCP could enhance the quality of life for many patients undergoing neoadjuvant therapy.
Exploring de-escalation strategies like this is critical for improving cancer care and tailoring treatments to individual risk profiles. Could this be a step toward redefining the standard for HER2+ breast cancer treatment?”
More posts featuring Francisco Esteva.
Dr. Francisco Javier Esteva is the Chief of the Division of Hematology and Medical Oncology at Lenox Hill Hospital and a Professor of Medicine at the Zucker School of Medicine. He also serves as the Director of Breast Cancer Translational Research at Northwell Health.
Before joining Northwell, he was a Research Professor at the NYU School of Medicine and Vice President of Clinical Development at Cellectis.
Dr. Esteva prioritizes patient-centered care by ensuring patients are fully informed about their pathology, staging, molecular tests, and treatment options, fostering collaborative decision-making.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023